<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01438086</url>
  </required_header>
  <id_info>
    <org_study_id>UCC-IGF-001</org_study_id>
    <secondary_id>2011-000480-27</secondary_id>
    <nct_id>NCT01438086</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Efficacy of Using Insulin-like Growth Factor-1 in Patients With a Heart Attack</brief_title>
  <acronym>RESUS-AMI</acronym>
  <official_title>A Randomised Trial Evaluating the Safety and Efficacy of a Single Low Dose of Intracoronary Insulin-like Growth Factor-1 Following Percutaneous Coronary Intervention for ST-Elevation Acute Myocardial Infarction (RESUS-AMI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College Cork</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College Cork</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      When a patient has a heart attack, a blockage occurs in a coronary artery that delivers&#xD;
      oxygen to the heart muscle. The heart muscle may weaken, causing heart failure. The body&#xD;
      naturally makes a protein called insulin-like growth factor-1 (IGF-1) that may protect the&#xD;
      heart muscle cells from dying and may prevent heart failure or lessen the damage that occurs.&#xD;
      IGF-1 is also available as a drug called mecasermin. In this study, heart attack patients&#xD;
      will be given either a dose of mecasermin or a placebo (inactive treatment) after their&#xD;
      coronary artery has been opened by a stent. The purpose of the study will be to evaluate the&#xD;
      safety of the therapy and to test if the therapy will prevent or lessen heart failure by&#xD;
      evaluating a cardiac magnetic resonance imaging (MRI) taken one day and eight weeks after the&#xD;
      heart attack.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2011</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum glucose measurement</measure>
    <time_frame>30 minutes after study drug administration</time_frame>
    <description>Safety outcome measure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent change in global left ventricular ejection fraction (LVEF) measured by quantitative cardiac magnetic resonance imaging (MRI)</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Efficacy outcome measure</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Heart Failure</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>mecasermin low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>mecasermin high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>saline placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mecasermin</intervention_name>
    <description>Intracoronary bolus</description>
    <arm_group_label>mecasermin low dose</arm_group_label>
    <other_name>rhIGF-1</other_name>
    <other_name>IGF-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mecasermin</intervention_name>
    <description>Intracoronary bolus</description>
    <arm_group_label>mecasermin high dose</arm_group_label>
    <other_name>rhIGF-1</other_name>
    <other_name>IGF-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% sodium chloride injection</intervention_name>
    <description>Intracoronary bolus</description>
    <arm_group_label>saline placebo</arm_group_label>
    <other_name>normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 - 75&#xD;
&#xD;
          -  Presents within 2-12 hours of at least 30 minutes of myocardial ischemic pain&#xD;
&#xD;
          -  ECG evidence of myocardial infarction&#xD;
&#xD;
          -  Undergoing percutaneous coronary intervention (PCI) for ST-elevation myocardial&#xD;
             infarction&#xD;
&#xD;
          -  Left ventricular ejection fraction during PCI of 40% or less&#xD;
&#xD;
          -  TIMI flow grade 3 in the infarct-related artery following reperfusion and stenting&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of prior myocardial infarction&#xD;
&#xD;
          -  Prior history of heart failure, left ventricular dysfunction or cardiomyopathy&#xD;
&#xD;
          -  Active or suspected neoplasia&#xD;
&#xD;
          -  Known impaired liver function&#xD;
&#xD;
          -  Cardiogenic shock&#xD;
&#xD;
          -  Estimated glomerular filtration rate &lt; 45 ml/min/1.73m2&#xD;
&#xD;
          -  History of hypoglycaemia requiring hospitalisation&#xD;
&#xD;
          -  History of primary insulin-like growth factor-1 deficiency or growth hormone disorders&#xD;
&#xD;
          -  Contraindication to cardiac magnetic resonance imaging&#xD;
&#xD;
          -  Pregnancy or nursing mothers&#xD;
&#xD;
          -  Known allergy to study drug or any of its inactive ingredients&#xD;
&#xD;
          -  Treatment with another investigational agent within 30 days of enrolment&#xD;
&#xD;
          -  Subjects unable or unwilling to comply with follow-up requirements of study&#xD;
&#xD;
          -  Subjects unable to provide written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noel Caplice, MB, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College Cork</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cork University Hospital</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>September 17, 2011</study_first_submitted>
  <study_first_submitted_qc>September 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2011</study_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University College Cork</investigator_affiliation>
    <investigator_full_name>Professor Noel Caplice</investigator_full_name>
    <investigator_title>Professor of Cardiovascular Sciences</investigator_title>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Myocardial Infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mecasermin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 19, 2017</submitted>
    <returned>June 29, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

